Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 14/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 14/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979172 | 0.86 | CHRNB2 (0.58) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14709894 | 0.80 | CHRNB2 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10214995 | 0.79 | GPR119 (0.41) | CHRNB2CHRNA3CHRNA4GPR119CHRNB4 | |
| SCHEMBL14791637 | 0.79 | GPR119 (0.41) | CHRNB2CHRNA3CHRNA4GPR119CHRNB4 | |
| SCHEMBL17992194 | 0.79 | GPR119 (0.41) | CHRNB2CHRNA3CHRNA4GPR119CHRNB4 | |
| SCHEMBL288005 | 0.79 | GPR119 (0.41) | CHRNB2CHRNA3CHRNA4GPR119CHRNB4 | |
| SCHEMBL14706990 | 0.79 | GPR119 (0.39) | CHRNB2CHRNA3CHRNA4GPR119CHRNB4 | |
| SCHEMBL288006 | 0.79 | GPR119 (0.41) | CHRNB2CHRNA3CHRNA4GPR119CHRNB4 | |
| SCHEMBL14709892 | 0.78 | TSHR (0.47) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL11993158 | 0.78 | GPR119 (0.41) | CHRNB2CHRNA3CHRNA4GPR119CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | CHRNB2 230/4885CHRNA3 308/4885CHRNA4 403/4885 |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | CHRNB2 230/4885CHRNA3 308/4885CHRNA4 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.